“Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas” (2009) Hematology Meeting Reports (formerly Haematologica Reports), 2(5). doi:10.4081/hmr.v2i5.749.